Letter to the Editor
Drug-eluting balloons for peripheral artery disease: A meta-analysis of 7 randomized clinical trials and 643 patients

https://doi.org/10.1016/j.ijcard.2013.01.247Get rights and content

Section snippets

Acknowledgments

The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology. Dr Biondi-Zoccai has consulted, lectured, and received career grant support from Medtronic.

References (9)

  • G. Biondi-Zoccai et al.

    Devices for infrainguinal endovascular therapy: menu à la carte or table d'hôte?

    J Endovasc Ther

    (2011)
  • S. Cassese et al.

    Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials

    Circ Cardiovasc Interv

    (2012)
  • G. Tepe et al.

    Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg

    N Engl J Med

    (2008)
  • M. Werk et al.

    Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial

    Circulation

    (2008)
There are more references available in the full text version of this article.

Cited by (13)

  • Paclitaxel-coated balloons angioplasties for extra-long femoropopliteal artery atherosclerotic lesions (> 30 ​cm):12 months outcomes from a single center

    2022, Journal of Interventional Medicine
    Citation Excerpt :

    Kaplan–Meier curves of primary patency and FF-CDTLR rates are shown in Figs. 1 and 2. Recent studies showed the superiority of PCBs as compared to standard angioplasty (plain old balloon angioplasty, POBA) in femoropopliteal ischemia.1–7 However, these studies were largely performed in relatively short lesions.

  • Drug-Coated Balloon Angioplasty in Clinical Practice for Below-the-Knee, Popliteal, and Crural Artery Lesions Causing Critical Limb Ischemia: 1-Year Results from the Spanish Luminor Registry

    2020, Annals of Vascular Surgery
    Citation Excerpt :

    Therefore, different clinical outcomes can be anticipated. Most clinical studies have demonstrated the anatomic benefits of DCBs over regular PTA balloons in terms of patency and clinically driven TLR reduction, mainly for the FP segment.3,4 Nevertheless, in patients with CLI, results of the first DCBs generation have not been clearly superior over those of PTA when clinical variables, such as amputation and mortality rates, are compared.12,13

View all citing articles on Scopus
View full text